Management of patients with immediate reactions to COVID-19 vaccines - 03/02/23
Key words : COVID-19, vaccine, allergy, management, immediate reaction, PEG, vocal cord dysfunction, urticaria, anaphylaxis, ISRR
Le texte complet de cet article est disponible en PDF.
Plan
Supported by an AAAAI Foundation Faculty Development Award (to C.A.S.). The funders played no role in any aspect of this article. |
|
Disclosure of potential conflict of interest: M. Greenhawt is a consultant for Aquestive; a member of physician/medical advisory boards for DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abelló, and Prota; an unpaid member of the scientific advisory council for the National Peanut Board and medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and a member of the Joint Taskforce on Allergy Practice Parameters. In addition, M. Greenhawt has received honorarium for lectures from ImSci and MedLearningGroup, and multiple state/local allergy societies. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 2
P. 413-415 - février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.